Literature DB >> 27034771

Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.

Thomas Karagiannis1, Eleni Bekiari1, Panagiota Boura1, Apostolos Tsapas2.   

Abstract

Entities:  

Year:  2015        PMID： 27034771      PMCID： PMC4785858          DOI： 10.1177/2042098615623915

Source DB:  PubMed          Journal:  Ther Adv Drug Saf        ISSN： 2042-0986


× No keyword cloud information.
  21 in total

1.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.

Authors:  Benjamin M Scirica; Deepak L Bhatt; Eugene Braunwald; P Gabriel Steg; Jaime Davidson; Boaz Hirshberg; Peter Ohman; Robert Frederich; Stephen D Wiviott; Elaine B Hoffman; Matthew A Cavender; Jacob A Udell; Nihar R Desai; Ofri Mosenzon; Darren K McGuire; Kausik K Ray; Lawrence A Leiter; Itamar Raz
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

2.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes.

Authors:  William B White; Christopher P Cannon; Simon R Heller; Steven E Nissen; Richard M Bergenstal; George L Bakris; Alfonso T Perez; Penny R Fleck; Cyrus R Mehta; Stuart Kupfer; Craig Wilson; William C Cushman; Faiez Zannad
Journal:  N Engl J Med       Date:  2013-09-02       Impact factor: 91.245

Review 3.  Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants.

Authors:  Shiying Wu; Ingrid Hopper; Marina Skiba; Henry Krum
Journal:  Cardiovasc Ther       Date:  2014-08       Impact factor: 3.023

4.  Cardiovascular effects of dipeptidyl peptidase-4 inhibitors in diabetic patients: A meta-analysis.

Authors:  Gianluigi Savarese; Pasquale Perrone-Filardi; Carmen D'Amore; Cristiana Vitale; Bruno Trimarco; Luca Pani; Giuseppe M C Rosano
Journal:  Int J Cardiol       Date:  2014-12-03       Impact factor: 4.164

5.  Cardiovascular safety of the dipetidyl peptidase-4 inhibitor alogliptin in type 2 diabetes mellitus.

Authors:  W B White; R Pratley; P Fleck; M Munsaka; M Hisada; C Wilson; V Menon
Journal:  Diabetes Obes Metab       Date:  2013-04-04       Impact factor: 6.577

6.  Cardiovascular and heart failure safety profile of vildagliptin: a meta-analysis of 17 000 patients.

Authors:  G McInnes; M Evans; S Del Prato; M Stumvoll; A Schweizer; V Lukashevich; Q Shao; W Kothny
Journal:  Diabetes Obes Metab       Date:  2015-09-10       Impact factor: 6.577

7.  Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials.

Authors:  M Monami; B Ahrén; I Dicembrini; E Mannucci
Journal:  Diabetes Obes Metab       Date:  2012-09-20       Impact factor: 6.577

8.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes.

Authors:  Jennifer B Green; M Angelyn Bethel; Paul W Armstrong; John B Buse; Samuel S Engel; Jyotsna Garg; Robert Josse; Keith D Kaufman; Joerg Koglin; Scott Korn; John M Lachin; Darren K McGuire; Michael J Pencina; Eberhard Standl; Peter P Stein; Shailaja Suryawanshi; Frans Van de Werf; Eric D Peterson; Rury R Holman
Journal:  N Engl J Med       Date:  2015-06-08       Impact factor: 91.245

9.  Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.

Authors:  Odd Erik Johansen; Dietmar Neubacher; Maximilian von Eynatten; Sanjay Patel; Hans-Juergen Woerle
Journal:  Cardiovasc Diabetol       Date:  2012-01-10       Impact factor: 9.951

10.  Design and baseline characteristics of the CARdiovascular Outcome Trial of LINAgliptin Versus Glimepiride in Type 2 Diabetes (CAROLINA®).

Authors:  Nikolaus Marx; Julio Rosenstock; Steven E Kahn; Bernard Zinman; John J Kastelein; John M Lachin; Mark A Espeland; Erich Bluhmki; Michaela Mattheus; Bart Ryckaert; Sanjay Patel; Odd Erik Johansen; Hans-Juergen Woerle
Journal:  Diab Vasc Dis Res       Date:  2015-03-15       Impact factor: 3.291
View more
  5 in total

1.  Metformin Safety Warnings and Diabetes Drug Prescribing Patterns for Older Nursing Home Residents.

Authors:  Andrew R Zullo; David D Dore; Roee Gutman; Vincent Mor; Carlos A Alvarez; Robert J Smith
Journal:  J Am Med Dir Assoc       Date:  2017-07-01       Impact factor: 4.669

Review 2.  A review of glucagon-like peptide-1 receptor agonists and their effects on lowering postprandial plasma glucose and cardiovascular outcomes in the treatment of type 2 diabetes mellitus.

Authors:  David R Owens; Louis Monnier; Markolf Hanefeld
Journal:  Diabetes Obes Metab       Date:  2017-07-11       Impact factor: 6.577

3.  Comparative safety for cardiovascular outcomes of DPP-4 inhibitors versus glimepiride in patients with type 2 diabetes: A retrospective cohort study.

Authors:  Hyouk-Jun Chin; Jin Hyun Nam; Eui-Kyung Lee; Ju-Young Shin
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

4.  Dipeptidyl peptidase-4 (DPP-4) inhibition with linagliptin reduces western diet-induced myocardial TRAF3IP2 expression, inflammation and fibrosis in female mice.

Authors:  Annayya R Aroor; Javad Habibi; Hemanth Kumar Kandikattu; Mona Garro-Kacher; Brady Barron; Dongqing Chen; Melvin R Hayden; Adam Whaley-Connell; Shawn B Bender; Thomas Klein; Jaume Padilla; James R Sowers; Bysani Chandrasekar; Vincent G DeMarco
Journal:  Cardiovasc Diabetol       Date:  2017-05-05       Impact factor: 9.951

5.  Effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors vs. Dipeptidyl Peptidase-4 Inhibitors in Frail People With Diabetes Who Were Recently Hospitalized.

Authors:  Stephen J Wood; J Simon Bell; Dianna J Magliano; Jonathan E Shaw; Matteo Cesari; Jenni Ilomaki
Journal:  Front Pharmacol       Date:  2022-07-12       Impact factor: 5.988
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.